Abstract
The impact of chronic kidney disease (CKD) or end-stage renal disease (ESRD) on patients receiving transvenous lead extraction (TLE) is not well-established. We performed a systematic review and meta-analysis to explore the association between CKD and all-cause mortality in TLE. We searched the databases of PubMed and EMBASE from inception to April 2022. Included studies were published TLE studies that compared the risk of mortality in CKD patients compared to control patients. Data from each study were combined using the random-effects model. Eight studies (5,013 patients)were included. Compared with controls, CKD patients had a significantly higher risk of overall all-cause mortality (hazard ratio [HR]=2.14, 95% confidence interval [CI]: 1.65-2.77, I2 =51.1%, p<.001). The risk of overall all-cause mortality increased with the severity of CKD for nonspecific CKD (HR=2.01, 95% CI: 1.49-2.69, I2 =53.4, p<.001) and ESRD (HR=2.79, 95% CI: 1.85-4.23, I2 =0%, p<.001). The risk of all-cause mortality in CKD is double at follow-up ≤1year (HR=1.99, 95% CI: 1.29-3.09, I2 =50.9%, p=.002) and higher at follow-up >1year (HR=2.36, 95% CI: 1.63-3.42, I2 =59.7%, p<.001). Our meta-analysis demonstrates a significantly increased risk of overall all-cause mortality in patients with CKD who underwent TLE compared to controls.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
